Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy
Crossref DOI link:
Published Online: 2016-12-20
Published Print: 2016-12
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Lowe, Jared R.
Perry, Daniel J.
Salama, April K. S.
Mathews, Clayton E.
Moss, Larry G.
Hanks, Brent A.
Funding for this research was provided by:
National Cancer Institute (1K08CA191063-01A1)
Melanoma Research Alliance (Young Investigator Award)
Alliance for Cancer Gene Therapy (Youg Investigator Award)